YB-1蛋白在肝癌细胞的表达部位及其意义

Expression and location of YB-1 protein in hepatocellular carcinoma and their clinical significance

目的探讨YB-1蛋白在肝细胞癌（Hepatocellular carcinoma，HCC）组织、2种肝癌细胞株、正常肝细胞株中的表达及其与肝癌患者临床参数的关系。方法采用免疫组化检测YB-1蛋白在58例HCC组织及相应例癌旁组织、20例正常肝组织中的表达；用Westernblot法检测上述HCC组织、癌旁组织、正常肝组织及肝癌细胞株QGY-7701、SMMC-7721、正常肝细胞株LO2中核移位YB-1蛋白表达。结果免疫组化显示在HCC组织，YB-1蛋白主要表达于癌细胞胞浆，其阳性率（72．4％，42／58）明显高于癌旁（41．4％，24／58及正常肝组织（35．0％，7／2）（P〈0．05）。其中18例（31．0％，18／58）HCC组织伴有明显YB-1核阳性表达，且核表达与HCC病理分级、门静脉癌栓、肿瘤大小相关（P〈0．05）。Westernblot检测同样证实核移位的YB-1蛋白在肝癌组织（0．474±0．107）显著高于癌旁组织及正常肝组织（P〈0．05）。核移位的YB-1蛋白在2种肝癌细胞株中均高于正常肝细胞株（P〈0．05），其差异较组织更为明显。结论YB-1蛋白在HCC中高表达及核移位可能促进了肝癌的发生发展，有可能成为肝癌治疗的新靶点。

Objective To study the expression levels of YB-1 protein in hepatocellular carcino- ma （HCC） tissues, tissues adjacent to tumour and normal liver tissues, and to explore the clinical sig- nificance. Methods To study the expression levels of YB-1 protein, immunochemistry was carried out on 58 HCC tissues and their corresponding adjacent tissues to tumour and on 20 normal liver tissues. The YB-1 protein with nuclear translocation was detected by Western blot in HCC tissues, tissues ad- jacent to tumour, normal liver tissues, HCC cell lines including QGY-7701 and SMMC-7721, and a normal hepatic cell line LO2. Results Positive signals of YB-1 protein were detected at a high level in HCC tissues （72.4%, 42/58） when compared to tissues adjacent to tumour （41.4%, 24/58） and to normal liver tissues （35%, 7/20） （P〈0.05）. The nuclear expression of YB-1 （31%, 18/58） was significantly correlated with the pathological grade, tumour size and portal venous invasion （P〈0.05）. Using Western blot, the YB-1 protein with nuclear translocation was expressed at a high- er level in HCC tissues （0. 474±0. 107） than in tissues adjacent to tumour and in normal liver tissues （P〈 0.05）. Similar results were obtained in HCC cell lines and the normal hepatic cell line （P〈0.05）. Conelusion The high expression of YB-1 in HCC and its nuclear translocation may be in- volved in human HCC progression. YB-1 may be a potential target for HCC treatment in the future.